Edition:
United States

Biotechnology & Medical Research

Stemline Therapeutics says SL-401 Phase 2 trial in AML results found SL-401 to be safe, well tolerated

Stemline Therapeutics Inc : SL-401 was found to be safe and well tolerated, and side effects were predictable and manageable .Stemline Therapeutics presents SL-401 lead-in results from its ongoing Phase 2 trial in AML in remission with MRD and Phase 2 trial in high-risk myeloproliferative neoplasms...

Tuesday, 6 Dec 2016 11:48am EST

Kiadis Pharma presents positive follow-up data of ATIR101 Phase II trial

Kiadis Pharma NV : Presents positive 1-year follow-up data of its pivotal Phase II Trial with ATIR101 . Significant reduction in Transplant Related Mortality and improvement in Overall Survival observed in comparison to an observational control group .Zero patients developed grade III-IV acute...

Tuesday, 6 Dec 2016 01:47am EST

Oryzon presents results from clinical trial with ORY-1001 to treat leukaemia

Oryzon Genomics SA : Presented on Monday the results from Phase I / IIA clinical trial with ORY-1001 in patients with recurrent or refractory acute leukaemia . The preliminary conclusions show that ORY-1001 is a highly active LSD1 inhibitor with strong differentiation-inducing activity in patients...

Tuesday, 6 Dec 2016 01:39am EST

Markets

  • Sectors
  • U.S.
  • Europe
  • Asia

Sector Summary

Upcoming Events

No related earnings announcements are currently scheduled within the next 7 days.